Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of 97% in Study of Patients Co-infected with HIV Given 12-week Combination Treatment of Daclatasvir and Sofosbuvir in ALLY-2 Trial
March 03, 2015 at 06:22 AM EST
A combination of two once-daily medications for chronic hepatitis C infection has been shown in newly released study results to cure ...
